440 Activity and safety of camrelizumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced non-small-cell lung cancer

440 Activity and safety of camrelizumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced non-small-cell lung cancer

Bibliographic Details
Main Authors:	Wei Wang, Peng Gao, Lu Sun, Guo Gui Sun, Jing Hao Jia, Xue Min Yao, Ming Da Chen, Wei Nan Yao
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

Case Report: Successful treatment of advanced hepatocarcinoma with the PD-1 inhibitor Camrelizumab
by: Wenling Ye, et al.
Published: (2023-07-01)

Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism
by: Jianqiong Yin, et al.
Published: (2022-04-01)

Case Report: Low-Dose Decitabine Plus Anti-PD-1 Inhibitor Camrelizumab for Previously Treated Advanced Metastatic Non-Small Cell Lung Cancer
by: Xin Yan, et al.
Published: (2020-10-01)

Safety and Efficacy of Transarterial Chemoembolization and Immune Checkpoint Inhibition with Camrelizumab for Treatment of Unresectable Hepatocellular Carcinoma
by: Zhang JX, et al.
Published: (2022-03-01)

Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies
by: Sonam Puri, et al.
Published: (2020-01-01)

Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer in China
by: Liu Qiao, et al.
Published: (2021-11-01)

Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer
by: Di ZHANG, et al.
Published: (2019-06-01)

Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review
by: Yiru Zhang, et al.
Published: (2023-01-01)

Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for  Non-small Cell Lung Cancer
by: Sixuan WU, et al.
Published: (2019-07-01)

Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer
by: Shuai Wang, et al.
Published: (2018-08-01)

Microwave ablation plus camrelizumab monotherapy or combination therapy in non-small cell lung cancer
by: Yahan Huang, et al.
Published: (2022-08-01)

Comparative Efficacy and Safety of Anti-PD-1/PD-L1 Immune Checkpoint Inhibitors for Refractory or Relapsed Advanced Non-Small-Cell Lung Cancer—A Systematic Review and Network Meta-Analysis
by: Koichi Ando, et al.
Published: (2020-12-01)

Total neoadjuvant treatment and PD-1/PD-L1 checkpoint inhibitor in locally advanced rectal cancer
by: Weiwei Xiao, et al.
Published: (2023-03-01)

PD‐L1 blockade by immune checkpoint inhibitors impairs sensitivity to osimertinib in EGFR‐mutant non‐small cell lung cancer cells
by: Dantong Sun, et al.
Published: (2022-12-01)

Lenvatinib Combined with the PD-1 Inhibitor Camrelizumab in the Treatment of Primary Liver Cancer Caused Hemorrhagic Exfoliative Gastritis
by: Hong Chen, et al.
Published: (2024-04-01)

Treatment of Multiple Primary Malignancies With PD-1 Inhibitor Camrelizumab: A Case Report and Brief Literature Review
by: Yuchen Wan, et al.
Published: (2022-07-01)

A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma
by: Wu-tong Ju, et al.
Published: (2022-09-01)

Efficacy and Safety of PD-1 Inhibitors Monotherapy for Elderly Patients with Advanced Non-small Cell Lung Cancer
by: SONG Pingan, CHEN Xiaoliang, YAO Yuan, GAO Jin, YANG Yang, CUI Hongchun, ZHANG Yi
Published: (2023-01-01)

Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis
by: Yan Li, et al.
Published: (2023-09-01)

Switching administration of anti‐PD‐1 and anti‐PD‐L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non‐small cell lung cancer: Case series and literature review
by: Shingo Kitagawa, et al.
Published: (2020-07-01)

bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti‐angiogenic agent apatinib combination therapy
by: Gehan Xu, et al.
Published: (2022-10-01)

Recurrent pleural effusion as a rare manifestation after prolonged PD1 inhibitor (camrelizumab)-based immunotherapy: A case report
by: Xiao-Hong Xie, et al.
Published: (2023-08-01)

Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial
by: Jun Ni, et al.
Published: (2023-04-01)

The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis
by: Lihu Gu, et al.
Published: (2019-06-01)

Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study
by: Boyu Qin, et al.
Published: (2024-01-01)

Immune checkpoint inhibitors for the treatment of non-small cell lung cancer brain metastases
by: Yuxi Wei, et al.
Published: (2023-07-01)

Progress of Immunotherapy Mechanisms and Current Evidence of PD-1/PD-L1  Checkpoint Inhibitors for Non-small Cell Lung Cancer with Brain Metastasis
by: Jiamin SHENG, et al.
Published: (2020-11-01)

Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer
by: Ofek Mussafi, et al.
Published: (2022-08-01)

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
by: Qing Tang, et al.
Published: (2022-09-01)

Safety and efficacy of immune checkpoint inhibitor rechallenge in advanced non-small cell lung cancer: a retrospective study
by: Jia Feng, et al.
Published: (2024-01-01)

Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China
by: Guiyuan Xiang, et al.
Published: (2021-12-01)

Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors
by: Quentin Giordan, et al.
Published: (2021-10-01)

Risk and safety profile in checkpoint inhibitors on non-small-cell lung cancer: A systematic review
by: Majernikova, SM
Published: (2024)

Efficacy and safety of immune checkpoint inhibitor monotherapy in elderly patients with non‐small cell lung cancer
by: Yasuhiro Chikaishi, et al.
Published: (2021-03-01)

Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients
by: Qiao Yang, et al.
Published: (2021-04-01)

Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1
by: Yi-Chi eKong, et al.
Published: (2014-05-01)

Targeting YAP/TAZ in Combination with PD-L1 Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC)
by: Kostas A. Papavassiliou, et al.
Published: (2023-03-01)

529 Impact of histology and PD-L1 status on immune checkpoint inhibitors in the treatment of non-small cell lung cancer
by: Seongho Kim, et al.
Published: (2023-11-01)

Efficacy of immune checkpoint inhibitors according to PD‐L1 tumor proportion scores in non‐small cell lung cancer
by: Seongho Park, et al.
Published: (2020-02-01)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021-09-01)